정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1045 | Recruiting | Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) | COVID-19 | Biological: Mesenchymal Stromal Cells Other: Supportive Care |
Phase 2 | Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute | OTHER | 66 | All | 18 Years | Houston Methodist Hospital, Houston, Texas, United States |
| 1044 | Recruiting | Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients | COVID-19 | Drug: Hydroxychloroquine + Metabolic cofactor supplementation Drug: Hydroxychloroquine + Sorbitol |
Phase 3 | ScandiBio Therapeutics AB, Istanbul Medipol University Hospital, Istanbul Umraniye Training and Research Hospital, Bakirkoy Dr. Sadi Konuk Research and Training Hospital, Dr. Lutfi Kirdar Kartal Training and Research Hospital, Bagcilar Training and Research Hospital, Kanuni Sultan Suleyman Training and Research Hospital, Alanya Alaaddin Keykubat University Alanya Training and Research Hospital, Canakkale 18 Mart University Health Research and Application Hospital, Monitor CRO | INDUSTRY | 400 | All | 18 Years | University of Health Sciences Istanbul Umraniye Training and Research Hospital, Istanbul, Turkey |
| 1043 | Withdrawn | Metformin Glycinate in Patients With MS or DM2 , Hospitalized With COVID-19 and SARS Secondary to SARS-CoV-2 | Type 2 Diabetes | Drug: metformin glycinate Drug: Placebo oral tablet |
Phase 2 | Laboratorios Silanes S.A. de C.V. | INDUSTRY | 0 | All | 18 Years | Hospital Juarez de Mexico, OPD, Mexico City, Mexico |
| 1042 | Completed | Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. | Severe Acute Respiratory Syndrome Coronavirus 2 | Drug: Metformin Glycinate Drug: Placebo oral tablet |
Phase 2 | Laboratorios Silanes S.A. de C.V. | INDUSTRY | 20 | All | 18 Years | The American British Cowdray Medical Center, I.A.P, Mexico City, Mexico |
| 1041 | Recruiting | Methylene Blue Treatment of COVID-19 | SARS-CoV2 | Drug: Methylene Blue Drug: Control Test |
Phase 2 | Fondazione Epatocentro Ticino | OTHER | 64 | All | 18 Years | Fondazione Epatocentro Ticino, Lugano, Ticino, Switzerland |
| 1040 | Recruiting | Methylprednisolone in COVID-19 Patients (Methyl19LGH) | SARS (Severe Acute Respiratory Syndrome) | Drug: Methylprednisolone Injectable Product | Not Applicable | Lahore General Hospital | OTHER_GOV | 200 | All | 18 Years ~ 80 Years | Muhammad Irfan Malik, Lahore, Punjab, Pakistan |
| 1039 | Completed | Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19 | Severe Acute Respiratory Syndrome (SARS) Pneumonia | Drug: Methylprednisolone Sodium Succinate Drug: Placebo solution |
Phase 2 | Fundacao de Medicina Tropical Dr. Heitor Vieira Dourado | OTHER | 416 | All | 18 Years | Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil |